HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Miguel Regueiro  ¹     Severine Vermeire  ²     David T. Rubin  ³     Marla C. Dubinsky  ⁴     Ailsa L Hart  ⁵     Joseph Wu  ⁶     Jesse Green  ⁷     John C. Woolcott     Kenneth J. Gorelick     Aoibhinn McDonnell  ⁸     Krisztina Lazin  ⁹     Laurent Peyrin-Biroulet  ^{10, 11    
1} Cleveland Clinic, Cleveland, United States
² University Hospitals Leuven, Leuven, Belgium
³ University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States
⁴ Icahn School of Medicine at Mount Sinai, New York, United States
⁵ St Mark’s Hospital, London, United Kingdom
⁶ Pfizer Inc, Groton, United States
⁷ Pfizer Inc, Collegeville, United States
⁸ Pfizer Ltd, Sandwich, Kent, United Kingdom
⁹ Pfizer AG, Zürich, Switzerland
¹⁰ University of Lorraine, CHRU-Nancy, Nancy, France
¹¹ University of Lorraine, Inserm, NGERE, Nancy, France

Topic
IBD

Session
Targeting immune cell trafficking in IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)